Format

Send to

Choose Destination
P T. 2016 Jan;41(1):43-50.

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

Abstract

Use of sodium polystyrene sulfonate (SPS) dominates the long-term treatment of hyperkalemia, but two new agents, sodium zirconium cyclosilicate and the recently FDA-approved patiromer, may offer potential advantages compared with SPS.

KEYWORDS:

hyperkalemia; patiromer; sodium polystyrene sulfonate; sodium zirconium cyclosilicate

PMID:
26765867
PMCID:
PMC4699486

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center